United States Angina Pectoris Drugs Market Insight
Published: 05 June 2026 | Report Format: Electronic (PDF)
The growth rate of the Angina Pectoris Drugs Market in the United States is expected to grow at a rate of 6.84% owing to the increasing prevalence of cardiovascular diseases, rising geriatric population, growing awareness regarding early cardiac care, and continuous advancements in anti-anginal therapies and cardiovascular drug development.
United States Angina Pectoris Drugs Market Insights Forecasts to 2035
- The United States Angina Pectoris Drugs Market Size Was Estimated USD 3.86 Billion in 2025
- The Market Size is Expected to Grow at a CAGR of around 6.84% from 2025 to 2035
- The United States Angina Pectoris Drugs Market Size is Expected to rise around USD 7.46 Billion by 2035
Notable Insights for the United States Angina Pectoris Drugs Market
• Based on the Segmentation by Drug Type, it can be observed that the Beta Blockers & Calcium Channel Blockers segment is taking lead in the United States Angina Pectoris Drugs Market in 2025, holding almost 56% of the total market share due to their widespread use in managing chronic stable angina and cardiovascular disorders.
• Based on the Segmentation by Application, it can be seen that Hospitals, Cardiology Clinics & Specialty Care Centers segment held a market share of about 63% in the United States Angina Pectoris Drugs Market in 2025, mainly driven by increasing diagnosis rates and demand for long-term cardiovascular disease management.
• The global revenue of Pfizer Inc. in fiscal year 2025 stood at nearly USD 63.5 billion backed by growing demand for cardiovascular medicines, specialty therapeutics, and chronic disease treatment solutions.
• Increasing investments in cardiovascular drug development, precision medicine, and advanced cardiac monitoring technologies will fuel the growth of the market in coming years, as next-generation angina therapies improve symptom management effectiveness up to 41% and reduce hospitalization risks up to 28%.
Download the eBook (ToC)
What Makes Decisions Advisors Research Unique?
• Intelligent Market Research Based on AI for Cardiovascular Therapeutics
Decisions Advisors offers intelligent market research which includes advanced analysis of cardiovascular drug technologies, anti-anginal therapies, cardiac disease management solutions, and AI-driven healthcare analytics. Our research identifies potential areas of business development, treatment adoption rates, competitive position analysis, and important strategic changes in the United States Angina Pectoris Drugs Market.
• Highly Effective Research Approaches with Accurate Forecast Analysis
The research process uses advanced methodologies such as primary research interview approaches, pharmaceutical industry research, tracking the cardiovascular therapeutics value chain, and data triangulation to deliver accurate market sizing, CAGR forecasting, investment analysis, and treatment forecasting. The study examines the demand for angina pectoris drugs across hospitals, specialty cardiac centers, clinics, and healthcare institutions throughout the United States.
• Highly Competitive Environment Analysis
In-depth analysis of key cardiovascular drug manufacturers, anti-anginal therapy innovations, clinical trial activities, product launch activities, and collaborations is included in the report. The report also covers healthcare regulations, cardiovascular research and development analysis, reimbursement trends, and new opportunities available in the United States Angina Pectoris Drugs Market.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United States Angina Pectoris Drugs Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United States Angina Pectoris Drugs Market
• Pfizer Inc.
• AstraZeneca PLC
• Novartis AG
• Bayer AG
• Johnson & Johnson
• Merck & Co., Inc.
• Bristol-Myers Squibb Company
• Sanofi S.A.
• Abbott Laboratories
• Amgen Inc.
Recent Developments:
• In November 2025, AstraZeneca PLC expanded cardiovascular research initiatives focused on innovative therapies for chronic coronary syndromes and angina management.
• In July 2025, Pfizer Inc. announced advancements in cardiovascular drug development programs aimed at improving long-term outcomes for patients with ischemic heart diseases.
Market Segmentation:
United States Angina Pectoris Drugs Market, By Drug Type
• Nitrates
• Beta Blockers
• Calcium Channel Blockers
• Antiplatelet Agents
• Novel Anti-Anginal Therapies
United States Angina Pectoris Drugs Market, By Technology
• Precision Cardiovascular Therapeutics
• AI-Based Patient Monitoring Systems
• Advanced Drug Delivery Technologies
• Digital Cardiac Health Platforms
• Remote Cardiovascular Care Solutions
United States Angina Pectoris Drugs Market, By Application
• Hospitals
• Cardiology Clinics
• Specialty Care Centers
• Ambulatory Surgical Centers
• Home Healthcare Settings
Expert Views:
The United States Angina Pectoris Drugs Market will experience growth owing to the increasing burden of cardiovascular diseases, rising aging population, and growing adoption of advanced cardiac care solutions. The combination of precision cardiovascular therapeutics, AI-driven patient monitoring technologies, innovative anti-anginal drugs, and digital healthcare platforms will enhance treatment effectiveness and drive demand across hospitals, cardiology clinics, specialty care centers, and home healthcare environments.
Author: Govind and Krishna By Spherical Insights and Consulting